CMPX compasstherapeutics.com: Enterprise Value to EBITDA Ratio
Compass Therapeutics creates unique antibodies to combat tumors by investing in the study of the cancer microenvironment. The historical EV/EBITDA trajectory demonstrates the business value dynamics, where 0.00 serves as the base parameter value. The biotech's strategy is based on developing bispecific drugs for solid tumors, targeting the high unmet demand segment of targeted immunotherapy and a network of partner clinics.
Summary analytical data breakdowns for compasstherapeutics.com (CMPX)
- stock price and consensus target price:
- company stock capitalization data:
- business book valuation details:
- debt and solvency information:
Debt to Equity Compass Therapeutics|CMPX - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Compass Therapeutics, Inc.|CMPX - Company Aggregate Debts|Debt to Book Capitalization Ratio Compass Therapeutics Corp|CMPX - Company Long-Term Indebtedness|Company Short-Term Debt Compass Therapeutics|Quick Liquidity Indicator compasstherapeutics.com
- financial results and valuation multiples details:
CMPX - Annual Net Income|Future Profit Compass Therapeutics|CMPX - Market Price to Net Income Ratio|Forward P/E Multiple Compass Therapeutics|CMPX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Compass Therapeutics Corp|CMPX - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Compass Therapeutics|CMPX - Earnings per share for the trailing year|Quarterly EPS earnings growth compasstherapeutics.com|CMPX - Earnings growth in current year|Net earnings per share growth forecast for next year Compass Therapeutics
Fundamental company analysis:CMPX (Compass Bio)
This indicator measures the total business value, including net debt, relative to operating profit before depreciation and amortization, determining the market premium paid for future growth. By analyzing the EV/EBITDA ratio, an investor assesses the resilience of Compass Therapeutics (CMPX) amidst fierce competition with pharma behemoths for leadership in developing innovative cancer immunotherapy methods.
Competitor analysis for Compass Therapeutics
ImmunityBio Corp - Enterprise Value to EBITDA Ratio|Immunocore Corp (IMCR) - Company Value to EBITDA|JANX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RCUS (arcusbio.com)|ZYME: EV/EBITDA Multiple|TNGX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Iovance|Enterprise Value to EBITDA Ratio Immatics Biotechnologies (IMTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xencor, Inc. (XNCR)|Enterprise Value to EBITDA Ratio replimune.com REPL|Lyell Immunopharma, Inc. - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Innate Pharma SA IPHA|PYXS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CGEN (Compugen Ltd.) - Enterprise Value to Operating Income Before Depreciation|IO Biotech, Inc. (IOBT) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA sutrobio.com (STRO)|Enterprise Value to EBITDA Ratio INKT|HOWL - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio IMMX (Immix Biopharma, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio ALXO|EV/EBITDA Multiple CUE (Cue Biopharma)|Business Value to Operating Income Before Depreciation PDSB|Sonnet BioTherapeutics Holdings Inc. - EV/EBITDA Multiple|Company Value to EBITDA MAIA Biotech|Liminatus Pharma Corp (LIMN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LAVA Therapeutics - Business Value to Operating Income Before Depreciation|NXTC (NextCure, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Leap Tx|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Intensity Therapeutics (INTS)|SNSE: Company Value to Operating Income Before Depreciation Ratio|Synthetic Biologics - Enterprise Value to EBITDA Ratio|Gritstone bio Inc. (GRTS) - Company Value to EBITDA|Kineta, Inc. - EV/EBITDA Multiple|neximmune.com (NEXI) - Enterprise Value to EBITDA Ratio|turnstonebio.com (TSBX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Vaccinex Inc. (VCNX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harpoon Tx
